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Secretion of RNAs in extracellular vesicles is a newly
recognized form of intercellular communication. A
potential regulatory protein for microRNA (miRNA)
secretion is the critical RNA-induced silencing com-
plex (RISC) component Argonaute 2 (Ago2). Here, we
use isogenic colon cancer cell lines to show that
overactivity of KRAS due to mutation inhibits locali-
zation of Ago2 to multivesicular endosomes (MVEs)
and decreases Ago2 secretion in exosomes. Mecha-
nistically, inhibition of mitogen-activated protein
kinase kinases (MEKs) I and II, but not Akt, reverses
the effect of the activating KRAS mutation and leads
to increased Ago2-MVE association and increased
exosomal secretion of Ago2. Analysis of cells
expressing mutant Ago2 constructs revealed that
phosphorylation of Ago2 on serine 387 prevents
Ago2-MVE interactions and reduces Ago2 secretion
into exosomes. Furthermore, regulation of Ago2 exo-
somal sorting controls the levels of three candidate
miRNAs in exosomes. These data identify a key reg-
ulatory signaling event that controls Ago2 secretion
in exosomes.
INTRODUCTION
Secretion of RNAs into the extracellular space is reported to
regulate cell physiology (Patton et al., 2015). Extracellular
RNAs are carried by RNA-binding proteins, lipoproteins, or
extracellular vesicles (EVs) (Arroyo et al., 2011; Turchinovich
et al., 2011; Valadi et al., 2007; Vickers et al., 2011).
MicroRNAs (miRNAs) are a prominent component of secreted
RNAs (Patton et al., 2015; Skog et al., 2008; Valadi et al.,
2007). Certain miRNAs are preferentially sorted into EVs,
including late-endosome-derived exosomes and shed microve-978 Cell Reports 15, 978–987, May 3, 2016 ª2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://sicles (MVs) (Patton et al., 2015). Exosomal miRNAs can affect
recipient-cell phenotypes, including gene expression, cancer
invasiveness, proliferation, and inflammatory responses (Patton
et al., 2015).
Mechanistically, it is unclear how miRNAs and miRNA-asso-
ciated proteins are sorted into exosomes. Some targeting
sequences depend on binding to sumoylated hnRNPA2B1 (Vil-
larroya-Beltri et al., 2013). In addition, 30-uridylated miRNAs are
preferentially sorted to exosomes in B cells (Koppers-Lalic
et al., 2014). However, in most cases, these targeting se-
quences are not present in secreted miRNAs (Cha et al.,
2015). The association of the RNA-induced silencing complex
(RISC) machinery with multivesicular endosomes (MVEs) (Gib-
bings et al., 2009) suggests another mechanism that could
control secretion of miRNAs and miRNA-mRNA complexes
via exosomes.
Argonaute (Ago) 2 is a key component of the RISC that can
directly degrademRNAby slicing (Meister, 2013). Ago2 accumu-
lates in cytoplasmic processing bodies (P-bodies), where addi-
tional binding interactions promote translational inhibition and
mRNA decay (Meister, 2013; Sen and Blau, 2005). Ago2 also
associates with MVEs in structures that have been termed
‘‘GW-bodies’’ due to the presence of GW182 but lack of other
P-body components (Gibbings et al., 2009). Recent reports
have demonstrated that Ago2 binds to miRNAs to generate
Ago2-miRNA complexes that are found in the extracellular
space. Although the majority of reports describe Ago2 as being
present in the extracellular space as a free protein (Arroyo et al.,
2011; Russo et al., 2012; Turchinovich et al., 2011), other reports
have shown that Ago2 and other RNA-processing proteins are
contained in secreted exosomes (Melo et al., 2014; Squadrito
et al., 2014).
Here, we demonstrate that KRAS-dependent activation of
MEK-ERK (mitogen-activated protein kinase kinase/extracel-
lular-signal-regulated kinase) signaling inhibits sorting of Ago2
and Ago2-dependent miRNAs into exosomes. These data
establish a molecular mechanism for regulation of Ago2 sorting
and miRNA loading into exosomes.creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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RESULTS
KRAS Regulates Ago2 Localization to MVEs
We recently demonstrated that the loading of specific protein
and miRNA cargos into exosomes is dependent on KRASmuta-
tional status (Cha et al., 2015; Demory Beckler et al., 2013). As a
class, RNA-binding proteins are greatly decreased in mutant
KRAS-cell-derived exosomes (Demory Beckler et al., 2013). To
determine whether KRAS activity affects RISC machinery asso-
ciation with MVEs, we performed confocal immunofluorescence
microscopy on wild-type and mutant KRAS-expressing colon
cancer cells (WTDKs-8 and MutDKO-1, respectively) (Figure 1A).
WTDKs-8 andMutDKO-1 cells were derived from DLD1 cells, which
are heterozygous for the G13D KRAS mutation, by homologous
recombination to remove mutant or WT KRAS genes (Shirasawa
et al., 1993). Colocalization of Ago2 with the MVE marker CD63
and P-body component DCP1a revealed a large increase in
Ago2-CD63 colocalization in WTDKs-8 compared to MutDKO-1
cells (Figure 1B). Conversely, Ago2 colocalization with DCP1a
was decreased in WTDKs-8 cells (Figure 1C). Colocalization of
DCP1a with CD63 was rarely observed (Figure 1D), consistent
with Gibbings et al. (2009). DCP1a-positive foci usually colocal-
ized with Ago2; however, not all Ago2-positive foci were DCP1a
positive (Figure 1E). Similar results were observed in another
isogenic colorectal cancer cell linemodel of KRASmutation (Fig-
ure S1A). Colocalization of Dicer or GW182 with CD63 revealed
that there was a 3-fold increase in GW182-CD63 colocalization
inWTDKs-8 cells but no effect of KRAS on Dicer-CD63 colocaliza-
tion (Figures 1F–1I).
To corroborate our imaging results, we performed sub-
cellular fractionation of post-nuclear extracts (PNEs) on a den-
sity gradient to separate P-bodies and MVEs (Figure 1J), as
described previously (Squadrito et al., 2014). P-body compo-
nents DCP1a and GW182 sedimented in less dense fractions
(1–6), compared to late-endosomal MVE markers Rab7 and flo-
tillin (fractions 7–9). Western blot analysis revealed that Ago2Figure 1. Mutant KRAS Regulates Ago2 Localization and Secretion
(A) Representative confocal immunofluorescence images of Ago2 (red), CD63 (bl
are adjacent to the full images. Arrows point to Ago2-CD63 colocalization and arro
for full images and 5 mm for insets.
(B–E) Quantitation of colocalizations from images, as indicated. nR 51 cells from
(F and G) Confocal images of Dicer (F) or GW182 (G) (red) and CD63 (blue) in WT
(H and I) Percent Dicer (H) or GW182 (I) colocalized with CD63 (nR 50 cells from
(J) Western blot analysis of MutDKO-1 and WTDKs-8 subcellular fractionations throu
Rab7), and P-body components (DCP1a and GW182).
(K) Relative intensities of Ago2 (green) and Rab7 (red) bands for WTDKs-8 (left) an
(L) Percentage of Ago2 in Rab7-positive fractions from three independent experi
(M and N) Representative western blots (M) and quantification (N) from three indep
from WTDKs-8 and MutDKO-1 cells. Ago2, GW182, and Dicer bands normalized to
(O) Representative western blots of total cell lysates from WTDKs-8 and MutDKO-1
(P) Quantification of Ago2 and pERK bands, normalized to total ERK from three
(Q) Western blot analysis of Ago2, Flotillin1 (Flot1), Tsg101, and CD63 from iodi
exosomes from WTDKs-8 cells.
(R) Fractions 6 and 7 from iodixanol density purification of 18-hr UC exosomes
performed for Ago2, Hsp70, and Flotillin1.
(S) Quantification of Ago2 bands, normalized to Hsp70 from three independent e
Graphs depict mean ± SEM. *p < 0.05; ***p < 0.001; n.s., not significant. Uncropp
for all figures.
See also Figure S1.
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However, significantly more Ago2 was present in MVE frac-
tions from WTDKs-8 cells compared to MutDKO-1 cells (Figure 1J).
Quantitation of the percentage of Ago2 andRab7 in each fraction
revealed that the percentage of Ago2 cofractionating with MVE
was increased by 3-fold in WTDKs-8 cells (Figures 1K and 1L).
Together, the biochemical and imaging data demonstrate that
mutant KRAS decreases Ago2-MVE association.
KRAS Regulates Ago2 Secretion in Exosomes
To test whether KRAS-regulated association of Ago2 and
GW182 with MVE affects their secretion into EVs, conditioned
media fromWTDKs-8 and MutDKO-1 cells were subjected to differ-
ential centrifugation (The´ry et al., 2006). The low-speed pellet
(10,000 3 g), which typically contains shed MVs, and the high-
speed pellet (100,000 3 g for 18 hr) containing ultracentrifuged
exosomes (UC exosomes) were collected. In some cases, the
UC exosomes were further sedimented in a density gradient
(5%–40% iodixanol) for 18 hr at 100,000 3 g, leading to equili-
bration according to vesicle density (DG exosomes [DG-exo]).
NanoSight analysis and transmission electron microscopy
revealed typical size profiles for exosomes and MVs that was
similar in both cell lines (Figures S1B and S1C); however,
MutDKO-1 cells secreted more UC exosomes compared to
WTDKs-8 cells (Figure S1D).
Comparison of equal numbers of UC exosomes by western
blot analysis revealed a decrease in Ago2 and GW182 in
MutDKO-1 exosomes compared to WTDKs-8 exosomes (Figures
1M and 1N), despite equivalent whole-cell Ago2 levels (Figures
1O and 1P). Similarly, UC exosomes isolated from MutHCT-116
had decreased Ago2 levels, compared to exosomes isolated
from the isogenic cell line WTHKe-3 (Figure S1E). There was no
significant difference in Dicer levels between WTDKs-8 and
MutDKO-1 exosomes (Figures 1M and 1N). The P-body protein,
DCP1a, was undetectable in exosomes (data not shown),
consistent with its lack of colocalization with MVEs (Figures 1Aue), and DCP1a (green) in WTDKs-8 or MutDKO-1 cells. Zooms from boxed areas
wheads point to CD63-positive foci without Ago2. Scale bars represent 10 mm
three independent experiments for all.
DKs-8 and MutDKO-1 cells.
three independent experiments).
gh a continuous iodixanol gradient (2.5%–30%) for Ago2, MVE (Flotillin 1 and
d MutDKO-1 (right) cell fractionations. Yellow represents overlapping fractions.
ments.
endent experiments analyzing equal numbers of MVs and UC exosomes (exo)
Hsp70 as a loading control.
cells.
independent experiments.
xanol density gradient (5%–40%) separation of 18-hr (left) and 2-hr (right) UC
were pooled, and western blot analysis of equal numbers of exosomes was
xperiments.
ed blots and enlarged images are shown in Supplemental Appendices A and B
and 1D) (Gibbings et al., 2009). Ago2 levels were similar, and
Dicer and GW182 were undetectable in MVs purified from
WTDKs-8 and MutDKO-1 cells (Figures 1M and 1N). These data
are consistent with regulation of RISC association with MVEs
by KRAS.
Since UC exosomes may contain non-vesicle-associated pro-
tein aggregates, and Ago2 can be present in bodily fluids as a
non-vesicular protein complex (Arroyo et al., 2011; Turchinovich
et al., 2011), we further purified UC exosomes by density
gradient (DG-exo; Figure 1Q). Analysis of WTDKs-8 DG-exo
revealed that Ago2 and exosomal markers cofractionate at the
expected exosome density (Figure 1Q). Very little Ago2 was de-
tected in denser fractions corresponding to protein aggregates
(Sung et al., 2015) or lighter fractions corresponding to soluble
proteins (Van Deun et al., 2014). Western blot comparison
of equal numbers of WTDKs-8 and MutDKO-1 DG-exo revealed
4-fold less Ago2 in MutDKO-1 exosomes (Figures 1R and 1S).
To further demonstrate Ago2 association with exosomes,
WTDKs-8 DG-exo were immunoprecipitated using an anti-CD63
antibody. The majority of Ago2 was coprecipitated and depleted
from the supernatant by the anti-CD63 antibody but not the
immunoglobulin G (IgG) control antibody (Figure S1F). Finally,
to determine whether Ago2 is on the inside or outside of our
purified exosomes, we used a dot-blot assay (Lai et al., 2015).
WTDKs-8 exosomes were spotted onto nitrocellulose and probed
with anti-Ago2 or anti-CD63 antibodies in the presence or
absence of 0.1% Tween 20 to permeabilize the vesicles. Consis-
tent with Ago2 being an internal exosome cargo, Ago2 was de-
tected at much higher intensity in the presence of detergent (Fig-
ure S1G, upper panel). Consistent with its known location on the
outside of exosomes, CD63 was detected in both the absence
and presence of Tween 20. We found similar results using exo-
somes purified from cells expressing mCherry-tagged Ago2
and probedwith an antibody against mCherry (Figure S1G, lower
panel).
MEK Signaling Downstream of KRAS Negatively
Regulates Ago2-MVE Interactions
KRAS is likely to signal through MEKI/II and downstream
ERK. Alternatively, Akt and p38-MAPK (mitogen-activated
protein kinase) are candidates, as they can phosphorylate
Ago2 and regulate its localization to P-bodies (Horman et al.,
2013; Zeng et al., 2008). To determine whether MEKI/II,
Akt, or p38-MAPK regulate Ago2 localization to MVEs down-
stream of KRAS, MutDKO-1 cells were treated for 4 hr with inhib-
itors to MEKI/II (PD0325901), Akt (triciribine), or p38-MAPK
(SB203580). As in Figure 1, colocalization of Ago2 with CD63
was minimal in untreated MutDKO-1 cells and significantly higher
in WTDKs-8 cells (Figures 2A and 2B). However, inhibition of
MEK1/2 in MutDKO-1 cells increased Ago2-CD63 colocalization
to levels observed in WTDKs-8 cells. By contrast, inhibition of
Akt only partially increased Ago2-CD63 colocalization. Inhibition
of p38-MAPK had no effect on Ago2-CD63 colocalization (Fig-
ures 2A and 2B). Increases in Ago2-CD63 colocalization were
paralleled by concurrent decreases in Ago2-DCP1a colocaliza-
tion in drug-treated MutDKO-1 cells (Figure 2C). These data sug-
gest that KRAS-MEK signaling shifts the localization of Ago2
from MVEs to P-bodies.To corroborate these data, triciribine- or PD0325901-treated
MutDKO-1 cells were subjected to subcellular fractionation. As
expected, MEKI/II inhibition increased the amount of Ago2
present in MVE fractions (Figures 2D–2F). Akt inhibition had a
small but insignificant effect on Ago2-Rab7 cofractionation (Fig-
ure 2F), suggesting that MEK I/II and not Akt is the major
signaling pathway downstream of KRAS that affects Ago2-
MVE association.
KRAS-MEK Signaling Affects Ago2 Secretion into
Exosomes
To determine whether MEKI/II regulates Ago2 sorting into exo-
somes, exosomes were collected from drug-treated cells. All
cell preparations were >90% viable at the time of conditioned
media collection (Figure S2A). There was no significant effect
of drug treatment on exosome size; however, Akt or MEKI/II in-
hibition caused an 2-fold increase in exosome secretion (Fig-
ure S2B). To analyze cargo differences, equal numbers of exo-
somes were analyzed by western blotting. Inhibition of MEK
I/II, but not Akt, led to Ago2 accumulation inMutDKO-1 exosomes,
comparable to the Ago2 levels in WTDKs-8 exosomes (Figures 2G
and 2H). Likewise, inhibition of ERK1/2 with FR180204 increased
Ago2 levels in MutDKO-1 exosomes (Figures S2C and S2D). Since
we collect exosomes in serum-free, growth-factor-free media,
cells without mutant KRAS have minimal activation of KRAS-
MEK-ERK signaling. To test whether these cells also downregu-
late Ago2 sorting to exosomes when KRAS-MEK-ERK signaling
is activated, we collected exosomes in OptiMEM media, which
is serum free but contains growth factors. Under these condi-
tions, WTDKs-8 and MutDKO-1 cells had equivalent activation of
ERK (Figure S2E) and equivalent Ago2 levels in exosomes
(Figure S2F).
Phosphorylation on S387 Inhibits Ago2 Localization
to MVEs
Since phosphorylation of Ago2 at serine 387 can induce Ago2
localization to P-bodies (Horman et al., 2013; Zeng et al.,
2008), we tested whether S387 phosphorylation is differentially
regulated in our isogenic cells. Western blots of cell lysates
from MutDKO-1 and WTDKs-8 cells with a phosphospecific anti-
body revealed an 2-fold increase in phospho-S387 Ago2 in
MutDKO-1 cells. This increase was inhibited by inhibitors of Akt,
MEK I/II (Figure 3A), or ERKI/II (Figures S3A and S3B). Further-
more, pAgo2 cofractionated with P-bodies in subcellular frac-
tionation experiments (Figure 2D). Thus, KRAS signaling drives
Ago2 S387 phosphorylation throughMEK, ERK, and Akt; howev-
er, only MEK/ERK signaling affects Ago2 sorting into exosomes
(Figures 2G, 2H, and S2D).
To study the effect of S387 phosphorylation on Ago2-MVE in-
teractions, mCherry-Ago2 constructs containing phosphomi-
metic (S387E) or phospho-resistant (S387A) mutations were ex-
pressed in MutDKO-1 cells. Similar to endogenous staining of
Ago2 (Figures 1 and 2), colocalization of WT- or S387E-Ago2
with CD63 was extremely low, and colocalization with DCP1a
was high in MutDKO-1 (Figures 3B–3D). However, colocalization
of S387A-Ago2 with CD63 and DCP1a was similar to that of
endogenous Ago2 in WTDKs-8 cells (Figures 3B–3D). Likewise,
GW182-CD63 colocalization in MutDKO-1 cells was increasedCell Reports 15, 978–987, May 3, 2016 981
Figure 2. MEK and ERK Signaling Downstream of KRAS Regulates Subcellular Ago2 Localization and Secretion into Exosomes
(A) Representative confocal images of Ago2 (red), CD63 (blue), andDCP1a (green) inWTDKs-8, MutDKO-1, orMutDKO-1 cells treatedwith 10 mM triciribine (Tri), 10 mM
PD-0325901 (PD), or 20 mM SB203580 (SB) for 4 hr. Zooms of boxed areas are to the right of full images. Arrows point to Ago2-CD63 colocalization, and
arrowheads point to CD63 positive foci without Ago2. Scale bars represent 10 mm (image) and 5 mm (zoom).
(B and C) Quantitation of colocalizations from images, as indicated (nR 52 cells from three independent experiments).
(D) Subcellular fractionation of MutDKO-1 cells treated with 10 mM triciribine (DKO1-Tri) or 10 mM PD-0325901 (DKO1-PD).
(E) Relative intensities of Ago2 (green) and Rab7 (red) bands.
(F) Percent Ago2 present in Rab7-positive fractions from three independent experiments.
(G) Western blot analysis of equal numbers of exosomes and total cell lysates (TCL) from WTDKs-8 and MutDKO-1 cells treated with the indicated compounds
for 48 hr.
(H) Quantitation of Ago2 band levels for exosomes in western blots normalized to Hsp70 from four independent experiments.
Graphs depict mean ± SEM *p < 0.05; **p < 0.01; ***p < 0.001; n.s., not significant. For (A), brightness was uniformly increased after analysis in all channels for
improved visualization.
See also Figure S2.
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Figure 3. Phosphorylation of Ago2 at Ser387 Regulates Ago2 Trafficking and Secretion
(A) Western blot analysis of total cell lysates from WTDKs-8, MutDKO-1, or MutDKO-1 cells treated with 10 mM triciribine (Tri) or PD-0325901 (PD) (Akt and MEK
inhibitors [inhib], respectively). Graph plots the ratio of pAgo2 to total Ago2 relative to that fromMutDKO-1 cells from three independent experiments. cntrl, control
(B–D) Immunofluorescent colocalization analysis of WTDKs-8 cells expressing mCherry-WT Ago2 (WT-Ago2) and MutDKO-1 cells expressing either mCherry-
WT, -S387A, or -S387E Ago2mutants (red) costained for DCP1a (green) and CD63 (blue). (B) Representative confocal images. Zooms of boxed regions are to the
right of the full images. Arrows point to Ago2-CD63 complexes, and arrowheads point to CD63-positive foci without Ago2. (C and D) Percent Ago2 colocalized
with CD63 (C) or DCP1a (D), as indicated (nR 50 cells from three independent experiments).
(E–G) Subcellular fractionation analysis. (E) Representative western blots from density gradient subcellular fractionation of MutDKO-1 cells expressing WT, S387E
(SE), or S387A (SA) Ago2. (F) Relative intensities of Ago2 (green) and Rab7 (red) bands. (G) Percent Ago2 in Rab7-positive iodixanol fractions from three
independent experiments.
(H) Representative western blot (WB) analysis of mCherry and actin levels in total cell lysates (TCL) from MutDKO-1 cells expressing mCherry-WT, -S387E,
or -S387A Ago2.
(legend continued on next page)
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with the expression of phospho-resistant (S387A) Ago2 (Figures
S3C and S3D). These results were confirmed by subcellular frac-
tionation (Figures 3E–3G).
Secretion of Ago2 into Exosomes Is Regulated by S387
Phosphorylation
To test whether S387 phosphorylation regulates Ago2 exosome
content, conditioned media were collected from MutDKO1 cells
stably expressing mCherry-WT, -S387E, or -S387A Ago2 (Fig-
ure 3H). The number or size of EVs purified from these cell lines
was not significantly different (Figure 3I). However, there was a
3-fold increase in S387A Ago2 found in MutDKO1 exosomes
compared to either WT- or S387E-Ago2 (Figures 3J and 3K).
There was a similar increase in GW182 in exosomes purified
from S387A-Ago2-expressing MutDKO1 cells (Figures 3J and
S3E). There was little effect of Ago2 phosphosite mutation on
the export of Ago2 into MVs (Figures 3J and 3K).
let-7a miRNA Distribution Is Regulated by KRAS
To test whether the KRAS-dependent localization of Ago2 regu-
lates miRNA distribution, we transfected fluorescently labeled
let-7a (Cy3-let-7a) intoWTDKs-8 andMutDKO-1 cells and assessed
colocalization with Ago2 and the MVE marker CD63 (Figure 4A).
Regardless of KRAS status, there was 80% colocalization
of Cy3-let-7a with Ago2 (Figure 4B). In WTDKs-8 cells, 90% of
let-7a-Ago2-positive foci colocalized with CD63 (Figure 4C).
However, in MutDKO-1 cells, less than 10% of let-7a-Ago2 com-
plexes colocalized with CD63. These data suggest that KRAS af-
fects both Ago2 and miRNA localization.
Ago2 Affects Secretion of Candidate miRNAs into
Exosomes
To test whether Ago2 regulates secretion of specificmiRNAs into
exosomes, we assessed the exosomal content of three candi-
date miRNAs in Ago2-knockdown (KD)WTDKs-8 cells (Figure 4D).
WTDKs-8 cells were chosen because they secrete 3-fold more
Ago2 into exosomes than MutDKO-1 cells (Figures 1 and 2).
Although the presence of Ago2 did not affect the number of
secreted exosomes, there was an 8-fold decrease in the total
content of small RNAs in exosomes isolated from Ago2-KD cells
(Figure 4E). To determine whether there was a further selective
change in let-7a, miR-100, and miR-320a levels by qRT-PCR,
we adjusted the levels of RNA to 5 ng in each sample. The
data revealed a significant decrease in let-7a and miR-100 and
no change in miR-320a levels in exosomes from Ago2-KD cells
(Figure 4F). Analysis of the samemiRNAs in total cellular RNA re-
vealed a small increase inmiR-320a but no change in let-7a and
miR-100 levels in KD cells compared to controls (Figure 4F).
Exosomes collected from MutDKO-1 cells stably expressing
mCherry-WT, -S387E, or -S387A Ago2 were also analyzed for
miRNA content. Compared to WT or S387A exosomes, there
was a small decrease of unclear significance in the total content(I–K) NanoSight analysis (I) and western blot analysis (J and K, equal vesicle numb
cells from three independent experiments.
Graphs depict mean ± SEM from three independent experiments. *p < 0.05; ***p
analysis in all channels for improved visualization.
See also Figure S3.
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ure 4G). When examining specific miRNAs by qRT-PCR, only
expression of S387A Ago2 had an effect on miRNA secretion
with an 5-fold increase in exosome levels of let-7a, miR-100,
andmiR-320a (Figure 4H). Therewas no effect of Ago2 phospho-
mutants on cellular expression of those miRNAs. Examination of
MVs from the same cells revealed an overall lower small RNA
content compared to exosomes (Figure 4G, lower panel). qRT-
PCR analysis of MV RNA did not yield detectable levels of let-
7a, miR-100, or miR-320 in three of the four samples assayed,
despite using the same amount of RNA as for exosomal RNA an-
alyses (Table S1). Overall, these data indicate that Ago2 phos-
phorylation downstream of KRAS-MEK signaling controls the
secretion of specific miRNAs into exosomes.
DISCUSSION
The mechanisms by which miRNAs are sorted into EVs are not
well defined. We find that Ago2 sorting into exosomes is regu-
lated by MEK-ERK signaling downstream of activated KRAS.
Phosphorylation of Ago2 on S387 specifically inhibits Ago2 as-
sociation with MVEs, diminishes secretion into exosomes, and
increases association with P-bodies. Both Ago2 levels and
Ago2 phosphorylation control the secretion of specific miRNAs
into exosomes. These data demonstrate that Ago2 can be selec-
tively sorted into exosomes and ascribe a critical function to
that event: transport of bound miRNAs for cellular secretion
(see model in Figure 4I).
Whether Ago2 is present in exosomes has been controversial.
In plasma, Ago2 is primarily found in non-vesicular-protein-RNA
complexes (Arroyo et al., 2011; Turchinovich et al., 2011).
Furthermore, only small amounts of Ago2 were found in exo-
somes isolated from monocytes (Gibbings et al., 2009). How-
ever, other investigators have identified Ago2 in exosomes
(Melo et al., 2014). Our finding that KRAS-MEK signaling inhibits
sorting of Ago2 to exosomes indicates that Ago2 is a bona fide
exosome cargo; however, very low levels may be detected,
due to signaling regulation. Indeed, very little Ago2 is detectable
in exosomes from cells with mutant KRAS compared to Ago2
levels in exosomes purified from isogenic WT cells (Figures 1
and S1). Furthermore, growth factor stimulation of cells express-
ing WT KRAS is also likely to inhibit Ago2 sorting into exosomes
(Figure S2) (Van Deun et al., 2014). One additional complication
in interpreting the results from various studies is whether there is
serum (exosome depleted or otherwise) in the collection media.
Since serum contains abundant vesicle-free Ago2, it may
contaminate vesicle preparations as an extravesicular-associ-
ated protein and mask intravesicular Ago2 (Van Deun et al.,
2014). Since we used serum-free, growth-factor-free media,
we did not have those complicating factors; thus, on density gra-
dients, we only observed significant Ago2 in the fractions con-
taining exosomes (Figures 1 and S1). Furthermore, our dot-bloters loaded) of exosomes purified from mCherry-WT, -S387E, or -S387A Ago2
< 0.001; n.s., not significant. For (B), brightness was uniformly increased after
(legend on next page)
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experiments indicate that Ago2 is primarily on the inside of ves-
icles in our exosome preparations (Figure S1).
Phosphorylation of Ago2 S387 previously has been shown to
inhibit slicing activity, promote translational repression, and pro-
mote colocalization with P-body components (Horman et al.,
2013; Zeng et al., 2008). Our study further shows that this phos-
phorylation event inhibits association of Ago2 with MVE and
prevents secretion into exosomes. Although we confirmed that
Akt activity affects phosphorylation of Ago2 S387 (Horman
et al., 2013), Akt did not affect secretion of Ago2 into exosomes,
whereas MEK and ERK did. We hypothesize that this difference
reflects different spatial locations of signaling events. Consistent
with this idea, KRAS-MEK-ERK signaling was shown to occur on
late endosomes (Lu et al., 2009; Nada et al., 2009). Control of
Ago2 tyrosine phosphorylation also occurs (R€udel and Meister,
2008), and identification of the relevant kinases may suggest
further spatial control. Finally, Ago2-KRAS interaction in the
endoplasmic reticulum was recently shown to control KRAS
levels and cellular transformation (Shankar et al., 2016), sug-
gesting a complex interaction between KRAS and Ago2 in multi-
ple cellular compartments.
Melo et al. (2014) found that RISC-loading complex proteins
Dicer, Ago2, and TRBP were present in exosomes from breast
cancer but not from normal patients. Similarly, we found Dicer
and Ago2 in exosomes from colon cancer cells, along with
the RISC machinery component GW182. Although Ago2 and
GW182 exosome levels were regulated by KRAS, Dicer levels
were not significantly changed (Figure 1). Furthermore, Ago2
phosphorylation controlled the export of GW182 into exosomes
(Figures 3J and S3E). These data suggest that distinct signaling
pathways may regulate sorting into exosomes of miRNA biogen-
esis (Dicer and TRBP) and RISCmachinery molecules (Ago2 and
GW182). Furthermore, our data predict that exosomes derived
from tumors with KRAS mutations are likely to contain lower
levels of Ago2, GW182, and miRNA than those secreted from tu-
mors with only WT KRAS. An important future direction will be to
determine whether this prediction holds in clinical samples.
In summary, our data demonstrate that oncogenic KRAS pro-
motes the phosphorylation of Ago2 and suppresses its secretionFigure 4. Ago2 Regulates miRNA Secretion into Exosomes
(A–C)MutDKO-1 andWTDKs-8 cells expressing Cy3-labeled let-7a (red) were immun
Zooms of boxed areas are to the right of the full images. Scale bars represent 10 m
(C) Percent Ago2-let-7a complexes colocalized with CD63 (nR 46 cells from thr
(D) Western blot showing Ago2 expression in total cell lysates (TCL) from contro
(E) Exosome (Exo) secretion rate of control or Ago2-KD cells, quantitated by Nan
those exosomes (lower graph).
(F) qRT-PCR of select miRNAs from exosomal and cellular RNA isolated from con
lines indicate no fold change. WT, mCherry-WT; SE, mCherry-S387E; SA, mChe
(G) Exosome secretion rate of mCherry-Ago2-expressing MutDKO-1 cell lines (upp
graph).
(H) qRT-PCR of the indicated miRNAs from exosomal and cellular RNA. Data for
Ago2-WT. Dotted lines indicate no fold change.
(I) Model depicting Ago2-dependent and Ago2-independent sorting of miRNAs do
normal cells or carcinoma cells without KRASmutations), Ago2-GW182-miRNA co
MEK activity onMVE, leading to Ago2 phosphorylation and a shift fromMVE to P-
miRNAs to exosomes. Ago2-independent mechanisms are also likely to control tr
Ago2 in MVs, it is unlikely to affect the sorting of Ago2-binding miRNAs into shed
Graphs depict mean ± SEM from three independent experiments. *p < 0.05; **p
See also Table S1.
986 Cell Reports 15, 978–987, May 3, 2016in exosomes. We show that sorting of specific miRNAs into exo-
somes is controlled by Ago2. Our results implicate Ago2 as a po-
tential major player in miRNA sorting into exosomes and identify
a key regulatory signaling mechanism.
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